Ten of the 20 largest charities in the US in 2014 were patient-assistance programs funded by drugmakers, accounting for more than 7.7% of the drugmakers' operating expenses, according to investment banking firm Bernstein. "This explains, in part, the drug industry focus on limiting patient out-of-pocket costs. Since it is the drug industry that pays a significant portion of these costs, restricting them would significantly improve profitability," according to the report.
Specialty pharmacies play an important role in patient care, and payer-aligned specialty pharmacies have the technology and clinical expertise to enhance the safety, quality and affordability of care for patients receiving specialty medications. See the full infographic.
Language in a bill reauthorizing FDA user fees would give makers of generic drugs more guidance and opportunities to meet with FDA officials during the drug development process. Other proposals for controlling drug prices include changing FDA rules to facilitate pre-approval communications between drugmakers and insurers.
Mike Lee, R-Utah, is among the Senate Republicans pushing for faster, deeper cuts to Medicaid funding, potentially leaving millions of Americans uninsured and pushing costs higher for states and hospitals.
AstraZeneca reported that durvalumab, an immunotherapy approved to treat bladder cancer, reduced the progression of lung cancer after chemotherapy or radiotherapy in a clinical trial. The company is eyeing the drug, branded Imfinzi, as a potential blockbuster.
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.
Contact PCMA Charles Cote
Vice President, Strategic Communications